NEW YORK CITY, NY / ACCESS Newswire / November 12, 2026 / Iovance Biotherapeutics (NASDAQ: IOVA) shareholders lost $5.25 per share - a 35.45% decline to a $9.56 close - on October 29, 2026, after the Company reported results from its Phase 2 IOV-LUN-202 clinical trial of lifileucel. If you suffered a loss on your Iovance investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Lifileucel is an investigational tumor infiltrating lymphocyte therapy, and the trial studied patients with previously treated non-squamous non-small cell lung cancer. The Company reported that one of the trial's subgroups responded at a rate of 11.4%. The treatment those patients normally receive produces a response rate of 12.8%.

Iovance had earlier described the data as positive. In the October 29, 2026 report, the Company described the data as consistent with previously reported results. Levi & Korsinsky is investigating potential securities law violations on behalf of IOVA investors.

IOVA investors who lost money can have their Iovance losses reviewed at no cost, or reach Joseph E. Levi, Esq. directly at jlevi@levikorsinsky.com or (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered billions of dollars for investors.

Frequently Asked Questions About the IOVA Investigation

Q: What is the IOVA securities fraud investigation about?
A: A securities investigation is pending concerning Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) regarding potentially materially false or misleading statements. Shares fell approximately 35.45% after the Company disclosed Phase 2 IOV-LUN-202 results for lifileucel that it described as consistent with previously reported results, causing losses for shareholders.

Q: Who is conducting the IOVA investigation?
A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased IOVA securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.

Q: Who is eligible to participate in the IOVA investigation?
A: Investors who purchased IOVA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do IOVA investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter?
A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my IOVA shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IOVA and sold at a loss may still participate in the investigation.

Q: What if my IOVA losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP